Abstract:The diagnostic criteria published by the PNS (Paraneoplastic Neurological Syndromes) Euronetwork in 2004 provided a useful classification of PNS, including paraneoplastic neuropathies. Subacute sensory neuronopathy (SSN) was the most frequently observed peripheral PNS, whereas other forms of neuropathy, as sensory polyneuropathy, sensorimotor polyneuropathy, demyelinating neuropathies, autonomic neuropathies, and focal nerve or plexus lesions, were less frequent. At the time of publication, the main focus was on onconeural antibodies, but knowledge regarding the mechanisms has since expanded. The antibodies associated with PNS are commonly classified as onconeural (intracellular) and neuronal surface antibodies (NSAbs). Since 2004, the number of antibodies and the associated tumors has increased. Knowledge has grown on the mechanisms underlying the neuropathies observed in lymphoma, paraproteinemia, and multiple myeloma. Moreover, other unrevealed mechanisms underpin sensorimotor neuropathies and late-stage neuropathies, where patients in advanced stages of cancer-often associated with weight loss-experience some mild sensorimotor neuropathy, without concomitant use of neurotoxic drugs. The spectrum of paraneoplastic neuropathies has increased to encompass motor neuropathies, small fiber neuropathies, and autonomic and nerve hyperexcitability syndromes. In addition, also focal neuropathies, as cranial nerves, plexopathies, and mononeuropathies, are considered in some cases to be of paraneoplastic origin. A key differential diagnosis for paraneoplastic neuropathy, during the course of cancer disease (the rare occurrence of a PNS), is chemotherapy-induced peripheral neuropathy (CIPN). Today, novel complications that also involve the peripheral nervous system are emerging from novel anti-cancer therapies, as targeted and immune checkpoint inhibitor (ICH) treatment. Therapeutic options are categorized into causal and symptomatic. Causal treatments anecdotally mention tumor removal. Immunomodulation is sometimes performed for immune-mediated conditions but is still far from constituting evidence. Symptomatic treatment must always be considered, consisting of both drug therapy (e.g., pain) and attempts to treat disability and neuropathic pain.

Neurological Paraneoplastic Syndrome Caused by Small Cell Lung Cancer: a Case Report

Paraneoplastic neurological syndrome and its impact on the treatment outcomes of small‐cell lung cancer: A single‐center retrospective analysis

Case report: Immune checkpoint inhibitor-induced paraneoplastic neurological syndrome in two patients: a case series

Conformational analysis of lecithin in vesicles by 13 C NMR.

Paraneoplastic Neurological Syndromes of the Central Nervous System: Pathophysiology, Diagnosis, and Treatment

Regarding 'the impact of sex on angioplasty and primary stenting for femoropopliteal occlusive disease: results of the DURABILITY II trial'.

Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review

Small cell lung cancer with panhypopituitarism due to ectopic adrenocorticotropic hormone syndrome: A case report

Clinical analysis of 15 patients with paraneoplastic neurological syndromes caused by lung cancer

Equivalence of conventional anti-picryl T suppressor factor in the contact sensitivity system and monoclonal anti-NP TsF3: their final non-specific effect via the T acceptor cell.

Paraneoplastic Neuropathies: What's New Since the 2004 Recommended Diagnostic Criteria

The Diagnostic Challenge of Small Cell Lung Cancer with Anti-Gamma-aminobutyric-acid B Receptor Encephalitis: a Case Report

A solution to Frege's puzzle

Updates in the Management of Paraneoplastic Syndrome

Agressive small cell neuroendocrine carcinoma of the neck: A case report

An Eight-Year Single-Center Experience

Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection.

Paraneoplastic antibodies targeting intracellular antigens

Paraneoplastic syndrome mimicking adult-onset Still's disease caused by advanced lung cancer: a case report

Paraneoplastic Diseases of the Central Nervous System

Paraneoplastic Cerebellar Degeneration Accompanied by Seropositivity for Anti-GAD65, Anti-SOX-1 and Anti-VGCC Antibodies Due to Small-cell Lung Cancer